A Novel, Selective, and Sensitive Vacuum Ultraviolet Method to Detect Trace and Ultra-Trace Levels of Moisture in Acetonitrile Used in Oligonucleotide Synthesis

2022-12-24 00:30:48 By : Ms. Emily Chen

© 2022 MJH Life Sciences and Chromatography Online. All rights reserved.

© 2022 MJH Life Sciences™ and Chromatography Online. All rights reserved. pure acetic acid

Webinar Date/Time: Thu, Dec 15, 2022 11:00 AM EST

Learn an alternative method for trace moisture determination in acetonitrile using a selective and sensitive vacuum UV GC detector!

Register Free: https://www.chromatographyonline.com/lcgc_w/vacuum

Oligonucleotide therapeutics have emerged in recent years as a powerful alternative to small-molecule and protein therapeutics, resulting in the development of innovative drugs against cancers and genetic diseases. Synthesis of oligonucleotides is automated, highly efficient, and carried out on solid phase supports using oligonucleotide synthesizers in four steps: detritylation, coupling, capping, and oxidation. The coupling efficiency of the synthesis method is very important and determines how long an oligonucleotide can be synthesized as well as the yield and quality of the final product. There are many factors that can affect coupling efficiency including the moisture content of acetonitrile, which is used as a diluent and wash in the coupling stage of synthesis. Strict control of moisture content in acetonitrile (<10ppm) is required for high yield and a high-quality product. In this presentation, an alternative method for trace and ultra-trace moisture determination in acetonitrile using a selective and sensitive vacuum UV GC detector will be discussed with limits of detection to <100ppb. Advantages over other techniques will be considered. Key Learning Objectives:

Dr. Richard Ladd is a senior leader, owner, and director of RML Consulting, as well as an independent consultant to the pharmaceutical industry specializing in pharmaceutical development, manufacturing, and new technology innovation. He has over 35 years of pharmaceutical industrial experience spanning all stages of new drug discovery, development, scale-up, manufacturing, supply, and commercialization. Dr. Ladd has an extensive track record of delivering in scientific, line, and project leadership roles across pharmaceutical R&D, regulatory CMC, the analytical instrument industry, and at the interface of academia and the public sector. He has extensive expertise in analytical and pharmaceutical development, regulatory CMC authoring, and reviewing regulatory submissions from first-in-human to NDA/MAA, as well as defending regulatory submissions and conducting prep-approval audit inspections of both manufacturing and analytical facilities. In addition, he has a passion for new technology development and adoption and is an impeccable technical problem solver with a proven track record of resolving many commercially significant problems. He has extensive experience with the EU, U.S., China, Japan, India, and other emerging markets. He is highly active, networked, and influential across an extensive portfolio of academic, industrial, healthcare, public sector, and policy-related matters. As a lucid communicator, Dr. Ladd sets and provides clarity on strategic direction, challenges the status quo, and drives improvement. He regularly presents at international meetings, most recently on the subjects supporting quality by design strategies with technology solutions in pharmaceuticals, technology adoption for technical trouble shooting, and driving efficiency and productivity to shorten development times by utilizing novel technological solutions.

2-Butanone oxime 99.5% liquid Register Free: https://www.chromatographyonline.com/lcgc_w/vacuum